framycetin has been researched along with Dyslipidemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chawla, S; Jain, A; Kalra, BS; Srivastava, S | 1 |
| Aggarwal, H; Dikshit, M; Jagavelu, K; Kumar, Y; Pathak, P | 1 |
2 other study(ies) available for framycetin and Dyslipidemia
| Article | Year |
|---|---|
Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Carbamates; Cholesterol; Dexamethasone; Drug Combinations; Dyslipidemias; Female; Framycetin; Genotype; Glycated Hemoglobin; Gramicidin; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quality of Life; Valine; Young Adult | 2019 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolome; Metabolomics; Metformin; Mice, Inbred C57BL; Mice, Knockout; Neomycin; Nitric Oxide; Nitric Oxide Synthase Type II; Nitrites; Pioglitazone | 2021 |